Opiate Dependence: Clinical Trials

90 trials for Opiate Dependence, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

76 completed, 5 unknown, 4 terminated, 4 withdrawn. 25 Not applicable, 23 Phase 2, 16 Phase 3, 11 Phase 4, 9 Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable25Completed 20, Withdrawn 3, Terminated 2
Phase 223Completed 19, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1
Phase 316Completed 15, Terminated 1
Phase 411Completed 10, Unknown 1
Phase 19Completed 7, Unknown 2
Early Phase 11Completed 1

Follow Opiate Dependence: new trials by email Literature Review of Opiate Dependence trials Research Report on Opiate Dependence

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage
Lidocaine, Lidocaine and Dexamethasone - Subarachnoid Hemorrhage, Aneurysmal, Headache
Phase 2RecruitingThe University of Texas Medical Branch, Galveston152026-01-022026-11-03
Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder
Accelerated intermittent theta-burst stimulation (aiTBS) - Opiate Dependence, Suicidal Ideation
Not applicableWithdrawnStanford University2024-01-012024-07-16
Project Relief: Developing Brain Stimulation as a Treatment for Chronic Pain
Real TBS to the mPFC, Sham TBS to the mPFC, Real TBS to the MC - Chronic Pain, Chronic Lower Back Pain
Not applicableCompletedWake Forest University Health Sciences382020-06-152023-05-12
The Effect of Self-Forgiveness on Self-Stigma in Addiction.
Six Step Model of Self-Forgiveness, Treatment as Usual (TAU) - Substance Use Disorders, Opiate Dependence
Not applicableCompletedUniversity of Pittsburgh1302019-08-012021-09-05
Impact of Lofexidine on Stress, Craving and Opioid Use
Lofexidine, Placebo - Opioid-use Disorder, Opiate Dependence
Phase 2CompletedMedical University of South Carolina1122019-06-262025-02-07
Remote Observed Dosing of Suboxone to Improve Clinical Practice
Suboxone Remote Observed Dosing, Suboxone Attention Control - Opioid-use Disorder, Opioid Dependence
Phase 1 / Phase 2CompletedUniversity of Pennsylvania162019-04-012023-07-27
Developing Brain Stimulation as a Treatment for Chronic Pain in Opiate Dependent
iTBS to the left dlPFC, Sham iTBS to the left dlPFC, cTBS to the mPFC - Chronic Pain, Opiate Dependence
Early Phase 1CompletedMedical University of South Carolina242019-02-222023-02-10
Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET
11UCB-J PET Scan - Opiate Dependence, Cocaine Dependence
Not applicableCompletedYale University412019-01-012024-07-16
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
Repetitive Transcranial Magnetic Stimulation, Sham rTMS - Opiate Dependence, Chronic Pain
Not applicableTerminatedMedical University of South Carolina72018-09-282022-02-14
Cognitive Function Before and After Opioid Reduction in Patients With Chronic Pain
Chronic Nonmalignant Pain, Cognitive Impairment
CompletedZealand University Hospital502018-01-012019-07-05
A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic
sofosbuvir/velpatasvir - Hepatitis C, Chronic, Hepatitis C
Phase 4CompletedCommunity Research Initiative of New England112017-10-112021-05-13
Neurobehavioral Measurement of Substance Users in Outpatient Treatment Setting
Four-Session Mind Freedom Plan, Treatment as usual therapy - Cocaine Dependence, Cocaine Use Disorder
Not applicableCompletedHunter Holmes Mcguire Veteran Affairs Medical Center352017-06-052018-09-07
Pilot Study of Contingency Management for Smoking Cessation
Contingency Management - Smoking, Tobacco Smoking
Not applicableCompletedKing's College London402016-10-012017-11-29
Medicinal Dependence and Chronic Pain: Addictive Evaluation in CETD
Opiate Dependence, Chronic Pain
CompletedUniversity Hospital, Brest1282016-06-032018-08-17
Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction
lofexidine administration in subjects seeking buprenorphine dose reduction - Substance Withdrawal Syndrome, Opiate Addiction
Phase 1CompletedUSWM, LLC (dba US WorldMeds)102016-06-012017-10-26
Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone
extended release naltrexone - Opiate Dependence
Phase 2 / Phase 3CompletedUniversity of Pennsylvania1462016-01-012021-01-28
Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence
Acceptance and Commitment Therapy, Information Motivation Behavioral Model - Opiate Dependence, Sexually Transmitted Diseases
Not applicableCompletedRhode Island Hospital142015-12-012018-08-29
Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers
SL spray, SL film - Opiate Dependence
Phase 1CompletedINSYS Therapeutics Inc472015-06-012015-09-03
Substance Dependence Satisfaction With Care and Quality Of Life
Opiate Dependence, Alcoholism
UnknownCentral Hospital, Nancy, France6002014-04-012016-09-09
Clinical Efficacy and Serum Proteomic Profiling of Suan-Zao-Ren Tang for Sleep Disturbance During Methadone Maintenance
Suan-Zao-Ren Tang, Suan-Zao-Ren Tang placebo - Opiate Dependence
Phase 2CompletedChina Medical University, Taiwan902013-07-012014-03-18

Showing 20 of 90. Sign in to see all of them.

Narrower conditions

Opioid-Related Disorders (90)  ·  Substance-Related Disorders (16)  ·  Cocaine-Related Disorders (11)  ·  HIV Infections (7)  ·  Chronic Pain (6)  ·  Heroin Dependence (6)  ·  Alcoholism (5)  ·  Behavior, Addictive (4)  ·  Hepatitis C (4)  ·  Acquired Immunodeficiency Syndrome (3)  ·  Substance Withdrawal Syndrome (3)  ·  Depression (2)  ·  Risk Reduction Behavior (2)  ·  Smoking Cessation (2)  ·  Back Pain (1)

Broader conditions

Chemically-Induced Disorders (90)  ·  Mental Disorders (90)  ·  Narcotic-Related Disorders (90)  ·  Substance-Related Disorders (74)  ·  Communicable Diseases (13)  ·  Infections (13)  ·  Blood-Borne Infections (12)  ·  RNA Virus Infections (12)  ·  Virus Diseases (12)  ·  Behavior (11)  ·  Genital Diseases (10)  ·  Urogenital Diseases (10)  ·  Pathological Conditions, Signs and Symptoms (9)  ·  Immune System Diseases (8)  ·  Immunologic Deficiency Syndromes (8)

Interventions

Buprenorphine (14)  ·  Naltrexone (10)  ·  Buprenorphine, Naloxone Drug Combination (9)  ·  vivitrol (9)  ·  Naloxone (6)  ·  Therapeutics (4)  ·  Methadone (3)  ·  Atomoxetine Hydrochloride (2)  ·  Modafinil (2)  ·  Sugars (2)  ·  Acceptance and Commitment Therapy (1)  ·  Analgesics, Opioid (1)  ·  Behavior Therapy (1)  ·  Carvedilol (1)  ·  Case Management (1)

Sponsors

Yale University (19)  ·  Indivior Inc. (6)  ·  Johns Hopkins University (5)  ·  Alkermes, Inc. (4)  ·  University of Pennsylvania (4)  ·  Kuopio University Hospital (3)  ·  Medical University of South Carolina (3)  ·  Organization to Achieve Solutions in Substance Abuse (OASIS) (3)  ·  The University of Texas Health Science Center, Houston (3)  ·  Butler Hospital (2)  ·  China Medical University, Taiwan (2)  ·  Friends Research Institute, Inc. (2)  ·  New York State Psychiatric Institute (2)  ·  Sorlandet Hospital HF (2)  ·  Albert Einstein College of Medicine (1)

Countries

United States (61)  ·  France (3)  ·  Malaysia (3)  ·  Norway (3)  ·  Russia (3)  ·  Taiwan (3)  ·  China (2)  ·  Finland (2)  ·  Austria (1)  ·  Denmark (1)  ·  Iran (1)  ·  Lithuania (1)  ·  United Kingdom (1)

Top investigators

Kenneth Silverman, Ph.D. (3)  ·  Bernard L. Silverman, MD (2)  ·  David A. Fiellin, MD (2)  ·  Diana L Sylvestre, MD (2)  ·  George E Woody, MD (2)  ·  Oistein Kristensen, MD (2)  ·  Richard S Schottenfeld, MD (2)  ·  Richard S. Schottenfeld, M.D. (2)  ·  Robert P Schwartz, M.D. (2)  ·  Ulrich Tacke, MD, PhD (2)  ·  Alexander Okhapkin, Prof. (1)  ·  Alexander Sofronov, Prof. (1)  ·  Alexey Egorov, Prof. (1)  ·  Amy E Colson, MD MPH (1)

Results publications

PMID 40342086, PMID 21782353, PMID 40833692, PMID 16401957, PMID 16963828, PMID 17107609, PMID 18586174, PMID 19721480, PMID 20513828, PMID 20598836, PMID 20707781, PMID 21320227, PMID 21491290, PMID 21529928, PMID 21749526, PMID 21924552, PMID 22029398, PMID 22065255, PMID 22079773, PMID 22134175, PMID 22864399, PMID 22945623, PMID 23036218, PMID 23260506, PMID 23701526, PMID 23891461, PMID 24045030, PMID 24219166, PMID 24239030, PMID 24521036, PMID 24607365, PMID 25090173, PMID 25189089, PMID 25330017, PMID 25562462, PMID 25703440, PMID 25901451, PMID 27574837, PMID 28358754, PMID 29536342, PMID 30920187, PMID 31715440, PMID 33233020, PMID 34737091, PMID 37231479, PMID 38180268, PMID 38616571

NIH funding

R01DA014718 (4), P50DA009262 (2), R01DA010746 (2), R01DA019497 (2), K23DA021512 (1), K23DA024050 (1), K23DA025049 (1), R01DA013108 (1), R01DA013441 (1), R01DA013636 (1), R01DA014537 (1), R01DA018696 (1), R01DA019436 (1), R01DA019511 (1), R01DA019934 (1)